Weight-loss supplements are rebranding as “GLP-1 boosters.” They’re nothing like Ozempic. If you had come across the ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) given to adolescents with obesity was associated with a one-third ...

Patients aged 10 to 17 years who are prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are more likely to have ...

Patients aged 10 to 17 years who are prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are more likely to have ...

This is just a sneak peek at the thousands of consumer insights available to CivicScience clients. Discover more data. The ...

It may not sound surprising that treating obesity in adolescents and teens may have positive mental health impacts, but ...

,A weight-loss drug more effective than Ozempic and Wegovy has recently been approved in Australia. The drug, tirzepatide, is ...

Neurogastrx believes its drug could treat one of the most troublesome side effects of one of the industry's biggest blockbusters. On Wednesday, the Boston-area biotech said that its experimental drug ...

The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.

In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications, particularly GLP-1 receptor agonists such as Ozempic and Wegovy. The global ...

Baby Boomers looking to put new money to work may wish to check out the broader basket of dividend stocks while interest ...

Wegovy, produced by Danish drugmaker Novo Nordisk, made a debut here on Tuesday, 16 months after the drug obtained regulatory ...